Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02048813 · MORE INFO

Limitations, agreements, and source contact

Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma · Source last updated 2026-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
point Of Contact
email
eatrials@jimmy.harvard.edu
organization
ECOG-ACRIN Statistical Office
phone
617-632-3012
title
Study Statistician
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
LTE60
restrictive Agreement
true
point Of Contact
email
eatrials@jimmy.harvard.edu
organization
ECOG-ACRIN Statistical Office
phone
617-632-3012
title
Study Statistician

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice